Evidence map›Paper›PMID 39911214›Full record

ArticleClinical, cosmetic and investigational dermatology2025

Trends and Associations of Chilblains Prevalence with Connective Tissue Diseases, Including COVID-19 Incidence.

Yahya Argobi

Abstract read
In one paragraph

Article in Clinical, cosmetic and investigational dermatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Yahya ArgobiDermatology Department, King Khalid University, Abha, Saudi Arabia.ORCID 0000-0001-5343-5372

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Chillblains, also known as perniosis, are inflammatory skin lesions that have long been associated with exposure to low temperatures. However, their co-occurrence with autoimmune illnesses and viral infections, particularly COVID-19, has received increased attention. This study was designed to examine chilblains' documented prevalence and association with autoimmune diseases and COVID-19. Methods: This was a descriptive cross-sectional study carried out at Mass General Brigham (MGB), an extensive integrated healthcare system situated in Greater Boston, Massachusetts. The study included patients with a confirmed diagnosis of chilblains from 2014 to 2021 and COVID-19 from 2020 to 2021. The study was approved by the Mass General Brigham Human Research Committee, ensuring compliance with ethical standards. Results: During the study, 24,711 charts were reviewed, identifying 1478 patients with chilblains, resulting in an overall registered prevalence of 0.02463%. The majority of chilblains patients were female (72.5%), with the highest proportion in the 31-30-year age group (31.3%). 169 (11.43%) patients were identified with autoimmune diseases, predominantly females (94.1%). The most prevalent condition among them was systemic lupus erythematosus (SLE) (52.6%). Among COVID-19-positive patients (n = 88,763), 30 were diagnosed with chilblains, leading to a prevalence of 0.033%. Females (66.7%) and individuals aged 40-50 (56.7%) were predominantly affected. Conclusion: This study found a low prevalence primarily among young females and a significant correlation with connective tissue disorders like SLE. The study also notes a rare occurrence of chilblains in COVID-19 patients, suggesting a possible association that requires further investigation, particularly regarding demographic patterns within this subgroup.

Indexed as

autoimmune diseaseschilblainsconnective tissue disordersCOVID-19prevalenceSLE

Identifiers

PMID39911214
PMCPMC11796437

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.